AIDS 2018 Track A abstract submission categories

Track A - Basic and Translational Research	
HIV Evolution and phylodynamics (Intra- and Inter-Host)	
A1	Viral origins, evolution and diversity
A2	Viral fitness and resistance
Virology	
A3	Entry (attachment, receptors and co-receptors, penetration and tropism)
A4	Viral replicative cycle (reverse transcription, integration, viral assembly and maturation)
A5	Transcriptional and gene expression regulation (including regulatory genes)
Immune responses (innate and adaptive)	
A6	Innate immunity
A7	Humoral immunity (including broadly neutralizing antibodies)
A8	Cellular immunity
A9	Mucosal immunity
Pathogenesis (immune function and dysfunction)	
A10	Systemic immune activation and inflammation
A11	T cell depletion and reconstitution, and immune ageing
A12	Microbiomes and microbial translocation
A13	Correlates of HIV susceptibility, disease progression, (biomarkers and genetics)
A14	HIV co-morbidities
A15	Systems biology approaches to HIV infection
Neuropathogenesis	
A16	Virology of CNS compartment
A17	Neuroimmunity
A18	Neurodegeneration
A19	Biomarkers and imaging
Latency and viral reservoirs	
A20	Viral mechanisms of HIV/SIV persistence and latency
A21	Host cellular factors and latency
A22	Cellular and tissue reservoirs of HIV/SIV
A23	Quantifying HIV/SIV reservoirs and rebounding virus
Cure strategies	
A24	Eliminating/Silencing latency
A25	Immunotherapy
A26	Vaccines
A27	Genetherapy
Natural protection against HIV and AIDS	
A28	HIV controllers (including post-treatment controllers) and long term non-progressors
A29	Highly exposed seronegative individuals (HESN)
A30	Correlates of immune protection
Transmission and Early infection	
A31	Mucosal transmission
A32	Vertical transmission
A33	Blood borne transmission
A34	Founder viruses/transmission bottleneck

A35	Evolution of immunity following acute HIV infection
A36	Seroreversion
Novel treatment and prevention strategies	
A37	Preclinical drug development, including prophylactic drug and microbicide development
A38	Nucleic acid-based HIV therapies
A39	Immunotherapy (including broadly neutralizing antibodies)
Vaccine development	
A40	Cell-based preventative vaccines
A41	Adjuvants
A42	Novel vectors and strategies
A43	Antibodies
A44	Correlates of immune protection
Super infections	
A45	HIV-1
A46	HIV-2
A47	Co-infection: TB and other mycobacteria
A48	Co-infection: Viral hepatitis
A49	Co-infection: STIs, including HPV
A50	Co-infection: Other
Diagnostic tools for immunological and virological monitoring of HIV infection	
A51	Novel assays of immune responses
A52	Novel approaches to assess viral load and ARV resistance/tropism
Animal models (excluding latency/reservoirs)	
A53	Viral determinants of SIV pathogenesis
A54	Animal models of transmission, disease progression and spontaneous control
A55	Novel animal/virus models for vaccine, cure research and antiviral development
Pharmacology of antiretrovirals	
A56	In-vitro activity
A57	Tissue penetration
A58	Pharmacodynamics